The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
|Articles|February 1, 2006
- Volume 0 0
Press-In Bottle Adapter
Advertisement
EPS Inc(Ivyland, Pa)recently introducedtheEPS Press-InBottle Adapter.The productallowshealth careprofessionalsto easilydispense liquidsfromstock bottles into oral syringes. Professionalsjust need to press the adapterinto the bottle's opening and attach theoral syringe to the adapter's port. Then,withdraw the dose of medication fromthe bottle. The EPs' Press-In BottleAdapter is available in 24-, 28-, and 33-mm sizes. Packaged in bags of 25, theproduct fits most TampAlerT and EPSPrescription Bottles and can be usedwith the EPS line of oral syringes. Formore information, call 800-523-8966, orvisit www.medi-dose.com.
Articles in this issue
almost 21 years ago
can you READ these Rxs?almost 21 years ago
Compounding HOTLINEalmost 21 years ago
A Quarter Century of Pharmacy Law—And the Fat Lady Is Singingalmost 21 years ago
It's Time for Education on Rx Drug Abusealmost 21 years ago
Improving Quality of Life for Psoriasis Patientsalmost 21 years ago
A Look at Diabetic Retinopathyalmost 21 years ago
The Graying of HIValmost 21 years ago
AutoCarouselalmost 21 years ago
Lexi-Comp Knowledge Solutionalmost 21 years ago
Refill TeleManagerAdvertisement
Related to this article
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5